title: [A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab].
abstract: The patient was a 73-year-old Japanese female diagnosed with stage IIIc primary peritoneal cancer. After undergoing total hysterectomy and bilateral oophorectomy, she received regimens consisting of paclitaxel (PTX) and carboplatin (CBDCA). She subsequently developed recurrence four years after the disease onset and was treated with PTX, CBDCA and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Bev). Although clinical remission was maintained with the administration of Bev monotherapy every three weeks, proteinuria was detected six months later, and gradually increased. The findings of a renal biopsy showed diffuse wrinkling and double contouring of the glomerular tufts under light microscopy, although no immune complex deposition was observed on immunostaining. Additionally, electron microscopy showed hypertrophy of glomerular endothelial cells and widening of the subendothelial spaces. These histopathological findings were fully consistent with those of reported patients treated with VEGF inhibitors. The proteinuria attenuated following the initiation of treatment with losartan. Therefore, the administration of renoprotective therapy contributed to the patient's ability to continue the anticancer regimen with Bev in this case.
authors.forename: Kotaro
authors.initials: K
authors.lastname: Haruhara
authors.forename: Nobuo
authors.initials: N
authors.lastname: Tsuboi
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Nakao
authors.forename: Kentaro
authors.initials: K
authors.lastname: Koike
authors.forename: Akira
authors.initials: A
authors.lastname: Fukui
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kawamura
authors.forename: Makoto
authors.initials: M
authors.lastname: Ogura
authors.forename: Takashi
authors.initials: T
authors.lastname: Yokoo
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009402:Nephrosis, Lipoid / Q000139:chemically induced* / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use; D042442:Vascular Endothelial Growth Factors / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel